Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00

Pharming Group (NASDAQ:PHAR)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $10.00, but opened at $9.79. Pharming Group shares last traded at $9.59, with a volume of 617 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 14th.

Pharming Group Stock Performance

The stock has a market capitalization of $652.98 million, a P/E ratio of -69.78 and a beta of 0.20. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $10.70 and a two-hundred day simple moving average of $11.36.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $71.83 million. On average, equities analysts forecast that Pharming Group will post -0.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC acquired a new stake in Pharming Group (NASDAQ:PHAR) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 11,715 shares of the company’s stock, valued at approximately $134,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.